Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Academic Article uri icon

Overview

abstract

  • 46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.

publication date

  • January 1, 1991

Research

keywords

  • Mesothelioma
  • Mitoxantrone
  • Pleural Neoplasms

Identity

Scopus Document Identifier

  • 0026320759

PubMed ID

  • 1782071

Additional Document Info

volume

  • 27

issue

  • 12